A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)

Carole Mercier, Piet Dirix, Piet Ost, Charlotte Billiet, Ines Joye, Peter Vermeulen, Yolande Lievens, Dirk Verellen, Carole Mercier, Piet Dirix, Piet Ost, Charlotte Billiet, Ines Joye, Peter Vermeulen, Yolande Lievens, Dirk Verellen

Abstract

Background: Bone metastases represent an important source of morbidity in cancer patients, mostly due to severe pain. Radiotherapy is an established symptomatic treatment for painful bone metastases, however, when conventional techniques are used, the effectiveness is moderate. Stereotactic body radiotherapy (SBRT), delivering very high doses in a limited number of fractions in a highly conformal manner, could potentially be more effective and less toxic.

Methods: This is a phase III, randomized-controlled, single-blind, multicenter study evaluating the response rate of antalgic radiotherapy for painful bone metastases and the acute toxicity associated with this treatment. A total of 126 patients will be randomly assigned to receive either the standard schedule of a single fraction of 8.0 Gy delivered through three-dimensional conformal radiotherapy or a single fraction of 20.0 Gy delivered through SBRT. Primary endpoint is pain response at the treated site at 1 month after radiotherapy. Secondary endpoints are pain flare at 24-48-72 h after radiotherapy, duration of pain response, re-irradiation need, acute toxicity, late toxicity, quality of life and subsequent serious skeletal events. In a supplementary analysis, patient-compliance for a paper-and-pencil questionnaire will be compared with an electronic mode.

Discussion: If a dose-escalated approach within the context of single fraction stereotactic body radiotherapy could improve the pain response to radiotherapy and minimize acute toxicity, this would have an immediate impact on the quality of life for a large number of patients with advanced cancer. Potential disadvantages of this technique include increased pain flare or a higher incidence of radiation-induced fractures.

Trial registration: The Ethics committee of the GZA Hospitals (B099201732915) approved this study on September 4th 2018. Trial registered on Clinicaltrials.gov ( NCT03831243 ) on February 5th 2019.

Keywords: Bone metastases; Pain; Spinal metastases; Stereotactic body radiotherapy.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study schema. Subjects who meet eligibility criteria and qualify for enrolment will be randomized as demonstrated

References

    1. Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(1):4–12. doi: 10.1016/j.prro.2016.08.001.
    1. Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev. 2004;(2):CD004721.
    1. Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126(3):547–557. doi: 10.1016/j.radonc.2018.01.003.
    1. Huisman M, van den Bosch MA, Wijlemans JW, van Vulpen M, van der Linden YM, Verkooijen HM. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2012;84(1):8–14. doi: 10.1016/j.ijrobp.2011.10.080.
    1. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer. 2007;7(12):949–960. doi: 10.1038/nrc2288.
    1. Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–1748. doi: 10.1016/j.ijrobp.2011.02.040.
    1. De Bleser E, Tran PT, Ost P. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol. 2017;27(6):587–595. doi: 10.1097/MOU.0000000000000441.
    1. Bennett AV, Jensen RE, Basch E. Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin. 2012;62(5):337–347. doi: 10.3322/caac.21150.
    1. Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):1730–1737. doi: 10.1016/j.ijrobp.2011.02.008.
    1. Raman S, Ding K, Chow E, Meyer RM, Nabid A, Chabot P, et al. A prospective study validating the EORTC QLQ-BM22 bone metastases module in patients with painful bone metastases undergoing palliative radiotherapy. Radiother Oncol. 2016;119(2):208–212. doi: 10.1016/j.radonc.2016.04.035.
    1. Cheon PM, Wong E, Thavarajah N, Dennis K, Lutz S, Zeng L, et al. A definition of "uncomplicated bone metastases" based on previous bone metastases radiation trials comparing single-fraction and multi-fraction radiation therapy. J Bone Oncol. 2015;4(1):13–17. doi: 10.1016/j.jbo.2014.12.001.
    1. Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017;124(1):11–17. doi: 10.1016/j.radonc.2017.05.012.
    1. Mercier C, Dirix P, Meijnders P, Vermeulen P, Van Laere S, Debois H, et al. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial) Radiat Oncol. 2018;13(1):152. doi: 10.1186/s13014-018-1096-9.
    1. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37(8):4078–4101. doi: 10.1118/1.3438081.
    1. Falchook AD, Green R, Knowles ME, Amdur RJ, Mendenhall W, Hayes DN, et al. Comparison of patient- and practitioner-reported toxic effects associated with Chemoradiotherapy for head and neck Cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517–523. doi: 10.1001/jamaoto.2016.0656.
    1. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–565. doi: 10.1200/JCO.2015.63.0830.
    1. Ibrahim JG, Chu H, Chen MH. Missing data in clinical studies: issues and methods. J Clin Oncol. 2012;30(26):3297–3303. doi: 10.1200/JCO.2011.38.7589.
    1. Atherton PJ, Burger KN, Pederson LD, Kaggal S, Sloan JA. Patient-reported outcomes questionnaire compliance in Cancer cooperative group trials (Alliance N0992) Clin Trials. 2016;13(6):612–620. doi: 10.1177/1740774516655101.
    1. Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review. Value Health. 2008;11(2):322–333. doi: 10.1111/j.1524-4733.2007.00231.x.
    1. Muehlhausen W, Doll H, Quadri N, Fordham B, O'Donohoe P, Dogar N, et al. Equivalence of electronic and paper administration of patient-reported outcome measures: a systematic review and meta-analysis of studies conducted between 2007 and 2013. Health Qual Life Outcomes. 2015;13:167. doi: 10.1186/s12955-015-0362-x.
    1. Berwouts D, De Wolf K, Lambert B, Bultijnck R, De Neve W, De Lobel L, et al. Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: a 3-arm randomized phase II trial. Radiother Oncol. 2015;115(2):272–278. doi: 10.1016/j.radonc.2015.04.022.
    1. Ryu S, Jin R, Jin JY, Chen Q, Rock J, Anderson J, et al. Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manag. 2008;35(3):292–298. doi: 10.1016/j.jpainsymman.2007.04.020.
    1. Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys. 2008;71(3):652–665. doi: 10.1016/j.ijrobp.2008.02.060.
    1. Bhattacharya IS, Hoskin PJ. Stereotactic body radiotherapy for spinal and bone metastases. Clin Oncol (R Coll Radiol) 2015;27(5):298–306. doi: 10.1016/j.clon.2015.01.030.
    1. Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, et al. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT) BMC Cancer. 2017;17(1):361. doi: 10.1186/s12885-017-3341-2.
    1. Erler D, Brotherston D, Sahgal A, Cheung P, Loblaw A, Chu W, et al. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. Radiother Oncol. 2018;127(2):304–309. doi: 10.1016/j.radonc.2018.03.030.
    1. Sprave T, Verma V, Förster R, Schlampp I, Bruckner T, Bostel T, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2018;128(2):274–282. doi: 10.1016/j.radonc.2018.04.030.
    1. Loblaw DA, Wu JS, Kirkbride P, Panzarella T, Smith K, Aslanidis J, et al. Pain flare in patients with bone metastases after palliative radiotherapy--a nested randomized control trial. Support Care Cancer. 2007;15(4):451–455. doi: 10.1007/s00520-006-0166-y.
    1. Gomez-Iturriaga A, Cacicedo J, Navarro A, Morillo V, Willisch P, Carvajal C, et al. Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: multicenter prospective observational study. BMC Palliat Care. 2015;14:48. doi: 10.1186/s12904-015-0045-8.
    1. Chiang A, Zeng L, Zhang L, Lochray F, Korol R, Loblaw A, et al. Pain flare is a common adverse event in steroid-naïve patients after spine stereotactic body radiation therapy: a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86(4):638–642. doi: 10.1016/j.ijrobp.2013.03.022.
    1. Owen D, Laack NN, Mayo CS, Garces YI, Park SS, Bauer HJ, et al. Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Pract Radiat Oncol. 2014;4(2):e143–e1e9. doi: 10.1016/j.prro.2013.05.006.
    1. Pan HY, Allen PK, Wang XS, Chang EL, Rhines LD, Tatsui CE, et al. Incidence and predictive factors of pain flare after spine stereotactic body radiation therapy: secondary analysis of phase 1/2 trials. Int J Radiat Oncol Biol Phys. 2014;90(4):870–876. doi: 10.1016/j.ijrobp.2014.07.037.
    1. Khan L, Chiang A, Zhang L, Thibault I, Bedard G, Wong E, et al. Prophylactic dexamethasone effectively reduces the incidence of pain flare following spine stereotactic body radiotherapy (SBRT): a prospective observational study. Support Care Cancer. 2015;23(10):2937–2943. doi: 10.1007/s00520-015-2659-z.
    1. Balagamwala EH, Naik M, Reddy CA, Angelov L, Suh JH, Djemil T, et al. Pain flare after stereotactic radiosurgery for spine metastases. J Radiosurg SBRT. 2018;5(2):99–105.
    1. Sahgal A, Atenafu EG, Chao S, Al-Omair A, Boehling N, Balagamwala EH, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013;31(27):3426–3431. doi: 10.1200/JCO.2013.50.1411.
    1. Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the spine oncology study group. Spine (Phila Pa 1976) 2010;35(22):E1221–E1229. doi: 10.1097/BRS.0b013e3181e16ae2.
    1. Faruqi S, Tseng CL, Whyne C, Alghamdi M, Wilson J, Myrehaug S, et al. Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors. Neurosurgery. 2018;83(3):314–322. doi: 10.1093/neuros/nyx493.
    1. Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol. 2009;27(30):5075–5079. doi: 10.1200/JCO.2008.19.3508.
    1. Image-guided radiosurgery or stereotactic body radiation therapy in treating patients with localized spine metastasis. NCT00922974. . Accessed on 07 July 2019.
    1. Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study (VERTICAL). NCT02364115. . Accessed on 07 July 2019.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi